“An increased uptake of biosimilars may lead to improved patient access to biologic therapies and potential savings for the US health care system.5 As a company dedicated to making medicines ...

“This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

“This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

Organon faces profitability challenges and revenue declines. The valuation appears fair given the weak revenue outlook. See ...

Organon management's focus shifted to aggressive debt reduction, suspending shareholder rewards. Read why I rate OGN stock a ...

The DJS Law Group reminds investors of a class action lawsuit against Organon & Co. ("Organon" or "the Company") (NYSE: OGN) ...

Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action ...

Notably, defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend.

On May 1, 2025, Organon released its first quarter 2025 financial results, announcing that management had reset the Company’s dividend payout, from $0.28 to $0.02 and would “redirect those ...

The company exceeded earnings per share (EPS) expectations with a reported EPS of $1.02, surpassing the forecast of $0.91. However, revenue fell short, coming in at $1.51 billion against the ...